A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A (P3.042)

CONCLUSIONS: OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/assessments and outcomes measures.Study Sponsored by: Allergan, Inc.Disclosure: Dr. Patel has received personal compensation for activities with Allergan Inc. Dr. Manack has received personal compensation for activities with Allergan Inc.
Source: Neurology - Category: Neurology Authors: Tags: Neural Repair and Neuro-rehabilitation: Clinical Source Type: research